rivaroxaban and Lacerations

rivaroxaban has been researched along with Lacerations* in 1 studies

Other Studies

1 other study(ies) available for rivaroxaban and Lacerations

ArticleYear
Preclinical safety and efficacy of andexanet alfa in animal models.
    Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:9

    Essentials There is currently no approved reversal agent for factor Xa (FXa) inhibitors Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors Andexanet reduced blood loss and anticoagulation markers in rivaroxaban-anticoagulated rabbits Andexanet was well tolerated in monkeys and rats, with no evidence of prothrombotic activity SUMMARY: Background Andexanet alfa is a recombinant modified form of factor Xa (FXa), designed to bind to and reverse the anticoagulant activity of FXa inhibitors. Objectives To evaluate the ability of andexanet to reverse the anticoagulant activity of rivaroxaban, and assess its pharmacokinetics (PK) and toxicity in animal models. Methods The effects of andexanet on blood loss, anti-FXa activity, rivaroxaban unbound plasma concentrations and other coagulation parameters were assessed in a rabbit liver laceration 'treatment' model. Andexanet was administered 10 min after blood loss was initiated. The toxicity of repeated administration of andexanet (up to 60 mg kg

    Topics: Animals; Antidotes; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Lacerations; Liver; Macaca fascicularis; Male; Rabbits; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Rivaroxaban

2017